Your Article Summary
Myriad Genetics Launches OnDose, Its Seventh Molecular Diagnostic Product
Myriad, 07/30/09
Myriad Genetics, Inc. announced the launch of OnDose, the Company's seventh molecular diagnostic product. OnDose utilizes a unique, proprietary technology to measure a patient's exposure to the chemotherapy drug, 5–Fluorouracil (5–FU), to help oncologists adjust and optimize dosing to maximize efficacy and reduce toxicity.
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
AstraZeneca submits US New Drug Application for ticagrelor, an investigational antiplatelet agent
AstraZeneca, 11/23/09
FDA Grants Emergency Use Authorization of the Prodesse ProFlu-ST(TM)
Gen-Probe, 10/30/09
Gyrus PlasmaKinetic bipolar coagulation device for liver resection
Australian and New Zealand Journal of Surgery, 11/13/09
Article Search
Sponsor


See Latest Articles


